监测外周血SCF对预测c-kit阳性上皮性卵巢癌化疗耐药的临床价值  

Clinical value of peripheral blood SCF in the prediction of chemoresistance of c-kit positive ovarian cancer

作　　者：彭光彩[1] 王晓雯[1] 易村犍[1] Peng Guangcai Wang Xiaowen Yi Cunjian(Department of Obstetrics and Gynecology, The First Affiliated Hospital of Yangtze University,Jingzhou 43430)

机构地区：[1]长江大学附属第一医院妇产科,荆州434300

出　　处：《现代妇产科进展》2016年第12期891-894,899,共5页Progress in Obstetrics and Gynecology

摘　　要：目的：：监测卵巢癌患者外周血中游离干细胞因子（ SCF）的浓度变化和c-kit蛋白在卵巢癌组织中的表达,探讨外周血SCF值对早期预测c-kit （＋）上皮性卵巢癌继发性化疗耐药的临床价值。方法：利用量子点双染免疫荧光（ QDs）检测106例卵巢癌组织中c-kit和SCF蛋白表达,ELISA法检测46例上述卵巢癌患者化疗期间冰冻保存的外周血SCF值,分析铂类为主的化疗药物敏感型和耐药型卵巢癌患者外周血SCF值与组织c-kit表达的差异。结果：继发性化疗耐药的上皮性卵巢癌组织中,c-kit（＋）表达率远高于化疗敏感组（29.27％ vs 10.8％,P＜0.05）,c-kit（＋）表达率随着FIGO分期的进展而升高（Ⅰ~Ⅱ期8.7％,Ⅲ~Ⅳ期25％,P＜0.05）。继发性化疗耐药组的外周血SCF值随铂类为主的化疗药物治疗而有升高的趋势,化疗敏感组的SCF值随之有下降的趋势；继发性化疗耐药组的外周血SCF均值高于化疗敏感组（ P＜0.05）。卵巢癌c-kit （＋）的外周血SCF值均值高于c-kit（-）组（P=0.018）,外周血SCF值在卵巢癌c-kit（＋）组随铂类为主的化疗耐药而升高。结论：卵巢上皮癌组织中c-kit蛋白阳性表达可能导致肿瘤对铂类化疗药物耐药；c-kit蛋白在肿瘤间质细胞内的阳性表达,预示卵巢上皮性癌化疗耐药微环境的形成和极差的临床结局。卵巢癌化疗期间,监测外周血SCF值升高可能是早期预测c-kit（＋）卵巢癌继发性化疗耐药的标记物之一。Objective：To monitor the changes in the concentration of free stem cell fac-tor （ SCF） in peripheral blood and the expression of c-kit protein in ovarian cancer tissues,and to investigate the clinical value of early prediction of c-kit （＋） in epithelial ovarian cancer （EOC） resistance to platinum-based chemotherapy by monitoring SCF in peripheral blood. Methods：Expressions of c-kit and SCF were retrospectively studied with quantum dots immuno-fluorescence histochemistry （ QDs-IHC） ,in paraffin-embeded tissue specimens from 106 cases of EOC. The plasma concentration of the SCF were measured with enzyme linked immuno-sor-bent assay （ ELISA） from 46 EOC. To investigate the difference of SCF value in peripheral ser-um and c-kit expression of EOC patients who were sensitive and resistant to platinum-based chemotherapy. Results：In epithelial ovarian cancer （ EOC） ,the positive expression rate of c-kit in the chemoresistance group was 29. 27%,it was statistically higher than chemosensitive group （10. 8%）（P〈0. 05）. The positive expression of c-kit in EOC was closely corralated with ad-vanced FIGO clinical stages and chemotherapy-sensitivity. The positive rate increased in ad-vanced stage （Ⅰ~Ⅱ8 . 7%,Ⅲ~Ⅳ25%） （ P〈0 . 05 ） . The mean plasma concentration of the SCF in the chemoresistance group was statistically higher than the chemosensitive group of EOC （ P〈0 . 05 ） . The plasma concentration of the SCF in the chemoresistance group was up-regula-ted after platinum-based chemotherapy. The mean value of the SCF in c-kit （＋） group was higher than that in c-kit （-） group in epithelial ovarian cancer（P=0. 018）,the plasma con-centration of the SCF in c-kit （＋） group was up-regulated after platinum-based chemotherapy. Conclusion：The abnormal expression of c-kit protein may play an important role in the progres-sion and chemoresistance of EOC. The positive expression of c-kit protein in ovarian cancer stromal cell indicated poor clinical outcome

关 键 词：卵巢上皮性癌 化疗耐药 化疗敏感性 C-KIT SCF 

分 类 号：R737.33[医药卫生—肿瘤]